Shunzhen Zheng

机构：Shandong Provincial Hospital, Shandong First Medical University · ORCID：0000-0002-3028-3430

发表论文 25 篇 · 总被引 320 次 · h-index 10

代表论文

• Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges (2024 · Cancers · 被引 63)
• MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells (2019 · World Journal of Gastroenterology · 被引 47)
• The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma (2017 · Oncotarget · 被引 38)
• Clinicopathological characteristics and surgical outcomes of sarcomatoid hepatocellular carcinoma (2020 · World Journal of Gastroenterology · 被引 35)
• Characterization of 9-Nitrocamptothecin Liposomes: Anticancer Properties and Mechanisms on Hepatocellular Carcinoma In Vitro and In Vivo (2011 · PLoS ONE · 被引 29)
• Diagnostic and Prognostic Values of MANF Expression in Hepatocellular Carcinoma (2020 · BioMed Research International · 被引 20)